Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

Overview of attention for article published in Cancer Research Communications, November 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 5 X users

patent: 1 patent

Readers on

mendeley: 12 Mendeley

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 4,284 followers.

strongly agree @schoffski! Lesson learned from olaratumab among others https://t.co/34p7bUowUP

RT @schoffski: It makes absolutely no sense to draw conclusions on the perceived efficacy of novel agents in sarcoma based on expansion coh…

It makes absolutely no sense to draw conclusions on the perceived efficacy of novel agents in sarcoma based on expansion cohorts in Phase I/II trials with only 25 patients included and not selected for subtype and/or molecular alteration. https://t.co/l…

Interesante estudio sobre uso de anticuerpo-droga en tumores sólidos avanzados. ¿Cómo afectará esto a la medicina oncológica? 🤔🔬 #InvestigarMás https://t.co/pjEywEXBtB

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.